Phase I/II Trial of Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer
Phase of Trial: Phase I/II
Latest Information Update: 15 Dec 2017
At a glance
- Drugs Ruxolitinib (Primary) ; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 18 May 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 18 May 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.